Literature DB >> 33392031

Heterogeneous parameters based on 18F-FET PET imaging can non-invasively predict tumor grade and isocitrate dehydrogenase gene 1 mutation in untreated gliomas.

Tao Hua1, Weiyan Zhou1, Zhirui Zhou2, Yihui Guan1, Ming Li1.   

Abstract

BACKGROUND: The present study aimed to explore the efficacy of easily obtained intratumoral heterogeneous parameters, other than regular semi-quantitative parameters, based on static O-(2-[18F]fluoroethyl)-l-tyrosine (18F-FET) positron emission tomography (PET) imaging in glioma grade and isocitrate dehydrogenase (IDH) gene 1 mutation prediction.
METHODS: Fifty-eight adult patients with untreated glioma (grades II-IV) who underwent preoperative 18F-FET PET/computed tomography (CT) imaging were enrolled in the present study. Eight semi-automatically obtained static PET imaging parameters after lesion delineation were chosen for analysis. These were: maximal tumor-to-background ratio (TBRmax), peak tumor-to-background ratio (TBRpeak), mean tumor-to-background ratio (TBRmean), coefficient of variation (COV), heterogeneity index (HI), the standard deviation of lesion standardized uptake value (SUVsd), metabolic tumor volume (MTV), and total lesion tracer standardized uptake (TLU). Pathological and immunohistochemical results were used as a reference. The receiver-operating characteristic analysis was used to investigate the predictive efficacy of these parameters in glioma grade and IDH1 mutation status.
RESULTS: TLU [area under the curve (AUC): 0.841, P<0.0001], TBRpeak (AUC: 0.832, P<0.0001), and HI (AUC: 0.826, P<0.0001) had the top 3 single-parameter predictive performance between grade II or III and grade IV glioma patients. Combinations of TBRmax, SUVsd, and TBRmean (AUC: 0.850, P<0.0001); HI, SUVsd, and MTV (AUC: 0.848, P<0.0001); and HI, SUVsd, and TLU (AUC: 0.848, P<0.0001) had the top 3 multiple-parameter predictive performance. SUVsd (AUC: 0.710, P=0.0028), TLU (AUC: 0.698, P=0.0074), and HI (AUC: 0.676, P=0.0159) had the top 3 single-parameter predictive performance in the IDH1 genotype. Combinations of TBRmax, SUVsd, and TBRmean (AUC: 0.821, P<0.0001); SUVsd and TBRmean (AUC: 0.804, P<0.0001); and SUVsd, HI, and TBRmean (AUC: 0.799, P<0.0001) had the top 3 multiple-parameter predictive performance.
CONCLUSIONS: These easily obtained and highly repetitive heterogeneous parameters based on static 18F-FET PET/CT imaging can non-invasively predict glioma grade and IDH1 mutation, crucial in treatment planning, and prognostic evaluation. 2021 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Entities:  

Keywords:  O-(2-[18F]fluoroethyl)-l-tyrosine (18F-FET); adults; glioma; heterogeneity; isocitrate dehydrogenase gene mutation (IDH gene mutation); positron emission tomography (PET)

Year:  2021        PMID: 33392031      PMCID: PMC7719943          DOI: 10.21037/qims-20-723

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  36 in total

Review 1.  Radiomics in Oncological PET/CT: Clinical Applications.

Authors:  Jeong Won Lee; Sang Mi Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-10-20

2.  Value of 18F-FDG heterogeneity for discerning metastatic from benign lymph nodes in nasopharyngeal carcinoma patients with suspected recurrence.

Authors:  Seung Hwan Moon; Young Seok Cho; Young-Ik Son; Yong Chan Ahn; Myung-Ju Ahn; Joon Young Choi; Byung-Tae Kim; Kyung-Han Lee
Journal:  Br J Radiol       Date:  2016-09-21       Impact factor: 3.039

3.  Association of Radiomics and Metabolic Tumor Volumes in Radiation Treatment of Glioblastoma Multiforme.

Authors:  Christopher J Lopez; Natalya Nagornaya; Nestor A Parra; Deukwoo Kwon; Fazilat Ishkanian; Arnold M Markoe; Andrew Maudsley; Radka Stoyanova
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-11-15       Impact factor: 7.038

4.  Static and dynamic 18F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status.

Authors:  Antoine Verger; Gabriele Stoffels; Elena K Bauer; Philipp Lohmann; Tobias Blau; Gereon R Fink; Bernd Neumaier; Nadim J Shah; Karl-Josef Langen; Norbert Galldiks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-17       Impact factor: 9.236

5.  Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy.

Authors:  Maria Lucia Calcagni; Guido Galli; Alessandro Giordano; Silvia Taralli; Carmelo Anile; Andreas Niesen; Richard Paul Baum
Journal:  Clin Nucl Med       Date:  2011-10       Impact factor: 7.794

6.  Integration of dynamic parameters in the analysis of 18F-FDopa PET imaging improves the prediction of molecular features of gliomas.

Authors:  Merwan Ginet; Timothée Zaragori; Pierre-Yves Marie; Véronique Roch; Guillaume Gauchotte; Fabien Rech; Marie Blonski; Zohra Lamiral; Luc Taillandier; Laëtitia Imbert; Antoine Verger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-16       Impact factor: 9.236

7.  Molecular definition of breast tumor heterogeneity.

Authors:  Michail Shipitsin; Lauren L Campbell; Pedram Argani; Stanislawa Weremowicz; Noga Bloushtain-Qimron; Jun Yao; Tatiana Nikolskaya; Tatiana Serebryiskaya; Rameen Beroukhim; Min Hu; Marc K Halushka; Saraswati Sukumar; Leroy M Parker; Karen S Anderson; Lyndsay N Harris; Judy E Garber; Andrea L Richardson; Stuart J Schnitt; Yuri Nikolsky; Rebecca S Gelman; Kornelia Polyak
Journal:  Cancer Cell       Date:  2007-03       Impact factor: 31.743

8.  Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.

Authors:  Jeanette E Eckel-Passow; Daniel H Lachance; Annette M Molinaro; Kyle M Walsh; Paul A Decker; Hugues Sicotte; Melike Pekmezci; Terri Rice; Matt L Kosel; Ivan V Smirnov; Gobinda Sarkar; Alissa A Caron; Thomas M Kollmeyer; Corinne E Praska; Anisha R Chada; Chandralekha Halder; Helen M Hansen; Lucie S McCoy; Paige M Bracci; Roxanne Marshall; Shichun Zheng; Gerald F Reis; Alexander R Pico; Brian P O'Neill; Jan C Buckner; Caterina Giannini; Jason T Huse; Arie Perry; Tarik Tihan; Mitchell S Berger; Susan M Chang; Michael D Prados; Joseph Wiemels; John K Wiencke; Margaret R Wrensch; Robert B Jenkins
Journal:  N Engl J Med       Date:  2015-06-10       Impact factor: 176.079

Review 9.  The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy.

Authors:  Norbert Galldiks; Ian Law; Whitney B Pope; Javier Arbizu; Karl-Josef Langen
Journal:  Neuroimage Clin       Date:  2016-12-18       Impact factor: 4.881

10.  Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0.

Authors:  Ian Law; Nathalie L Albert; Javier Arbizu; Ronald Boellaard; Alexander Drzezga; Norbert Galldiks; Christian la Fougère; Karl-Josef Langen; Egesta Lopci; Val Lowe; Jonathan McConathy; Harald H Quick; Bernhard Sattler; David M Schuster; Jörg-Christian Tonn; Michael Weller
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-12-05       Impact factor: 9.236

View more
  4 in total

1.  MGMT promoter methylation status shows no effect on [18F]FET uptake and CBF in gliomas: a stereotactic image-based histological validation study.

Authors:  Shuangshuang Song; Yi Shan; Leiming Wang; Ye Cheng; Hongwei Yang; Guoguang Zhao; Zhenguang Wang; Jie Lu
Journal:  Eur Radiol       Date:  2022-02-22       Impact factor: 7.034

2.  Integrated CT Radiomics Features Could Enhance the Efficacy of 18F-FET PET for Non-Invasive Isocitrate Dehydrogenase Genotype Prediction in Adult Untreated Gliomas: A Retrospective Cohort Study.

Authors:  Weiyan Zhou; Qi Huang; Jianbo Wen; Ming Li; Yuhua Zhu; Yan Liu; Yakang Dai; Yihui Guan; Zhirui Zhou; Tao Hua
Journal:  Front Oncol       Date:  2021-11-19       Impact factor: 6.244

3.  Perfusion magnetic resonance imaging in the differentiation between glioma recurrence and pseudoprogression: a systematic review, meta-analysis and meta-regression.

Authors:  Jun Zhang; Yulin Wang; Yan Wang; Huafeng Xiao; Xinjing Chen; Yifei Lei; Zhebin Feng; Xiaodong Ma; Lin Ma
Journal:  Quant Imaging Med Surg       Date:  2022-10

4.  Predicting cancer malignancy and proliferation in glioma patients: intra-subject inter-metabolite correlation analyses using MRI and MRSI contrast scans.

Authors:  Changliang Su; Shihui Li; Xiaowei Chen; Chengxia Liu; Mehran Shaghaghi; Jingjing Jiang; Shun Zhang; Yuanyuan Qin; Kejia Cai
Journal:  Quant Imaging Med Surg       Date:  2021-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.